Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Fineline Cube Dec 21, 2025
Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025
Company Deals

Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round

Fineline Cube Dec 26, 2022

China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...

Company Drug

MindRank AI Receives FDA Approval for MDR-001 Clinical Study in Obesity

Fineline Cube Dec 26, 2022

Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA...

Company Medical Device

Hangzhou Biotest Receives FDA EUA for COVID-19 Antigen Self-Testing Reagent

Fineline Cube Dec 26, 2022

China-based Hangzhou Biotest Biotech Co., Ltd has announced receiving an Emergency Use Authorization (EUA) from...

Company Deals

Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE

Fineline Cube Dec 26, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...

Company Deals

Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China

Fineline Cube Dec 26, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...

Company Drug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Fineline Cube Dec 23, 2022

The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ:...

Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Company Drug

Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication

Fineline Cube Dec 23, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...

Company Deals

Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries

Fineline Cube Dec 23, 2022

China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...

Company Deals

MSD and Kelun Biotech Ink Record-Breaking ADC Deal

Fineline Cube Dec 23, 2022

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...

Policy / Regulatory

NMPA and GAC Release Notification on Import and Export Management of Narcotic Drugs

Fineline Cube Dec 23, 2022

The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...

Company Drug

Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

Fineline Cube Dec 23, 2022

China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Approved by US FDA

Fineline Cube Dec 23, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand

Fineline Cube Dec 23, 2022

Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...

Drug

Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab

Fineline Cube Dec 23, 2022

Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...

Company Deals

Qitan Tech Raises RMB 700 Million in Series C Financing Led by Meituan

Fineline Cube Dec 23, 2022

Qitan Tech, a nanopore gene sequencer maker based in Chengdu, has reportedly raised RMB 700...

Company Drug

Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval

Fineline Cube Dec 23, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from...

Company Drug

Tonghua Dongbao Receives NMPA Approval for THDBH151 Clinical Study in Gout and Hyperuricemia

Fineline Cube Dec 23, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced receiving approval from the National Medical Products...

Company Deals

Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance

Fineline Cube Dec 23, 2022

China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...

Company Drug

BioNTech Ships First COVID-19 Vaccine Batches to China

Fineline Cube Dec 22, 2022

BioNTech is reportedly in the process of shipping the first batches of its COVID-19 vaccines...

Posts pagination

1 … 517 518 519 … 600

Recent updates

  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.